Moderna’s mFlusiva Becomes First mRNA Flu Shot Cleared by FDA
FDA approves mFlusiva, Moderna’s first mRNA flu vaccine for adults 50+. Available soon for the 2026 season with strong trial results.
/ 25 items
#MRNA↓
Moderna Beats Revenue Estimates on Strong COVID Sales, but Shares Drop on Norovirus Setback
Moderna reported $145M Q2 revenue, beating $103M estimates on strong COVID vaccine sales. Shares fell after norovirus vaccine missed key trial goal.
Moderna Shares Surge as Oncology Pipeline Ignites Investor Optimism
Piper Sandler raised its price target on Moderna from $69 to $77, maintaining an Overweight rating. Strong momentum in the oncology pipeline is fueling the rally.
Profit-Taking Hits Moderna Stock After mRNA-1010 Wins Unanimous FDA Panel Backing
Decision due Aug 5, 2026. Potential 2026–27 launch.
Moderna Strengthens Commercial Leadership Ahead of Flu and Norovirus Vaccine Launches
Moderna names Ester Banque, ex-Zoetis/Novartis, as Chief Commercial Officer as it prepares for potential 2027 launches of combined flu-COVID, standalone flu, and norovirus vaccines. FDA advisory on mFLUSIVA this week.
Moderna Stock Surges as Hantavirus Vaccine Research Lights Up After Cruise Ship Outbreak
Moderna stock rises as it works on a hantavirus vaccine after a cruise outbreak, but the disease is rare and vaccines will take years.